Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Mark Wahrenbrock

Clinical Pathology San Diego, CA Medical Doctor

NPI 1104267145 CMS profile 1220356

8901 Activity Rd Ste 205, San Diego, CA 92126

Open in the dashboard

General payments

$129,516

133 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Wahrenbrock of San Diego, CA is reported in the CMS Open Payments database as having received $129,516 across 133 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Clinical Pathology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $28,279 39
2024 General $25,350 24
2023 General $27,170 24
2022 General $30,745 26
2021 General $14,073 19
2020 General $3,900 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Wahrenbrock
  • Clinical Pathology median
  • Middle half of Clinical Pathology
  • National median

In program year 2025, general payments to Mark Wahrenbrock were reported at $28,279. Among 92 Clinical Pathology profiles paid that year, the median was $116 and the middle half received between $39 and $1,974.

Show as a table
Year Mark Wahrenbrock Clinical Pathology median Middle half National median
2019 $0 $103 $33–$2,625 $163
2020 $3,900 $608 $26–$3,550 $114
2021 $14,073 $188 $25–$3,680 $132
2022 $30,745 $88 $35–$2,579 $149
2023 $27,170 $113 $30–$1,856 $160
2024 $25,350 $119 $30–$2,508 $164
2025 $28,279 $116 $39–$1,974 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. CSL Plasma Inc. $80,799 87 payments
  2. CSL Behring $48,718 46 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Consulting Fee $129,516 133 payments

Records

133 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Pathology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record